We are live on ! Find out more
ORTX

Orchard Therapeutics plc American Depositary Shares
ORTX

Delisted

ORTX was delisted on the 23rd of January, 2024.

Back to rankings

62 hedge funds and large institutions have $755M invested in Orchard Therapeutics plc American Depositary Shares in 2019 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 26 increasing their positions, 10 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 10

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

9% less funds holding

Funds holding: 68 → 62 (-6)

11% less capital invested

Capital invested by funds: $848M → $755M (-$92.5M)

28% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 18

Holders
62
Holders Change
-6
Holders Change %
-8.82%
% of All Funds
1.36%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.09%
New
13
Increased
26
Reduced
10
Closed
18
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$22.7M
2
Federated Hermes
Federated Hermes
Pennsylvania
+$14.7M
3
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$12.7M
4
Citadel Advisors
Citadel Advisors
Florida
+$9.01M
5
FCMI
Foresite Capital Management IV
California
+$7.78M

Top Sellers

Rank Fund Capital Flow
1
VC
Vivo Capital
California
-$18.4M
2
VMI
VHCP Management III
New York
-$9.46M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$3.21M
4
MIM
Monashee Investment Management
Massachusetts
-$3.08M
5
PI
Putnam Investments
Massachusetts
-$2.25M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$242M – – –
DM
2
Deerfield Management
New York
$106M – – –
RCM
3
RA Capital Management
Massachusetts
$62.1M +$1.62M +11,615 +2%
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$58.9M +$12.7M +90,812 +22%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$39.9M +$22.7M +162,728 +94%
CA
6
CHI Advisors
New York
$35.5M +$41.7M +299,021 New
Artisan Partners
7
Artisan Partners
Wisconsin
$20.7M +$1.15M +8,245 +5%
DCM
8
Driehaus Capital Management
Illinois
$17.4M +$442K +3,168 +2%
Westfield Capital Management
9
Westfield Capital Management
Massachusetts
$12.8M +$457K +3,277 +3%
Federated Hermes
10
Federated Hermes
Pennsylvania
$12.5M +$14.7M +105,000 New
Temasek Holdings
11
Temasek Holdings
Singapore
$11.9M – – –
PI
12
Putnam Investments
Massachusetts
$11.8M -$2.25M -16,126 -14%
Wellington Management Group
13
Wellington Management Group
Massachusetts
$11.2M +$1.07M +7,696 +9%
Baillie Gifford & Co
14
Baillie Gifford & Co
United Kingdom
$11M – – –
ACH
15
ArrowMark Colorado Holdings
Colorado
$9.89M +$1.66M +11,860 +17%
CAM
16
Cormorant Asset Management
Massachusetts
$8.02M -$768K -5,500 -8%
Citadel Advisors
17
Citadel Advisors
Florida
$7.67M +$9.01M +64,586 New
FCMI
18
Foresite Capital Management IV
California
$6.63M +$7.78M +55,770 New
PA
19
Perceptive Advisors
New York
$6.2M – – –
Massachusetts Financial Services
20
Massachusetts Financial Services
Massachusetts
$6.06M -$27.5K -197 -0.4%
BBA
21
Baker Bros. Advisors
New York
$4.82M – – –
Millennium Management
22
Millennium Management
New York
$4.55M -$952K -6,823 -15%
AG
23
Artal Group
Luxembourg
$4.16M – – –
PC
24
Polar Capital
United Kingdom
$4.16M +$2.79M +20,000 +133%
CC
25
Casdin Capital
New York
$3.68M +$2.93M +21,000 +210%
1
2 3 4

ORTX Hedge Fund Activity: Q3 2019 in Review

62 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Orchard Therapeutics plc American Depositary Shares (ORTX) for Q3 2019, worth a combined $755M — down 11% from $848M a quarter earlier.

Sellers outnumbered buyers: 18 funds closed out of ORTX and 13 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 26 added.

The largest buyer was Adage Capital Partners, adding an estimated $22.7M. The largest seller was Vivo Capital, exiting entirely with an estimated $18.4M sold.

  • 62 institutional investors held Orchard Therapeutics plc American Depositary Shares (ORTX) as of Q3 2019, down from 68 in Q2 2019.
  • Funds reported $755M of Orchard Therapeutics plc American Depositary Shares stock for Q3 2019, down 11% quarter-over-quarter.
  • 13 funds opened new Orchard Therapeutics plc American Depositary Shares positions in Q3 2019 and 18 closed out, a net change of -5 holders.
  • The largest Orchard Therapeutics plc American Depositary Shares buyer in Q3 2019 was Adage Capital Partners, an estimated $22.7M added.
  • The largest Orchard Therapeutics plc American Depositary Shares seller in Q3 2019 was Vivo Capital, an estimated $18.4M sold.

Based on aggregated 13F filings for Q3 2019.